Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – Still a Buy?

Capricor Therapeutics Inc (NASDAQ:CAPR) shares gapped up before the market opened on Tuesday . The stock had previously closed at $13.67, but opened at $15.11. Capricor Therapeutics shares last traded at $15.05, with a volume of 1,851,624 shares.

Analyst Ratings Changes

CAPR has been the topic of a number of recent research reports. Cantor Fitzgerald lifted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Trading Up 1.9 %

The firm has a market cap of $633.35 million, a PE ratio of -13.26 and a beta of 4.08. The company has a 50 day moving average price of $14.41 and a 200 day moving average price of $13.87.

Institutional Trading of Capricor Therapeutics

Several large investors have recently bought and sold shares of CAPR. Vanguard Group Inc. boosted its position in shares of Capricor Therapeutics by 44.4% in the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after buying an additional 700,243 shares in the last quarter. Farallon Capital Management LLC purchased a new position in shares of Capricor Therapeutics during the fourth quarter valued at approximately $31,056,000. Geode Capital Management LLC boosted its position in Capricor Therapeutics by 37.8% during the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock worth $12,139,000 after acquiring an additional 241,279 shares during the last quarter. Altium Capital Management LLC lifted its stake in shares of Capricor Therapeutics by 150.5% during the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock worth $9,853,000 after purchasing an additional 429,000 shares during the period. Finally, Woodline Partners LP acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth $8,693,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.